Welcome to our dedicated page for Oncocyte Corporation news (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte Corporation stock.
Oncocyte Corporation (OCX) is a pioneering precision diagnostics company dedicated to the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics aimed at facilitating clinical decision-making in the early detection of cancer. The company focuses on molecular tests that address high unmet needs in the diagnosis of lung, breast, and bladder cancers, conditions where current diagnostic standards are often ambiguous, costly, and invasive. Oncocyte's tests are developed based on a proprietary set of biomarkers, designed to differentiate between benign and malignant nodules or masses.
Oncocyte’s flagship products include:
- DetermaIO™: A gene expression test that assesses the tumor microenvironment to predict response to immunotherapies.
- DetermaCNI™: A blood-based monitoring tool for therapeutic efficacy in cancer patients.
- VitaGraft™: A blood-based solid organ transplantation monitoring test.
- GraftAssure™: A research-use-only monitoring test for solid organ transplantation.
The company has made significant strides in expanding its diagnostic capabilities and achieving key regulatory and commercial milestones. In 2023, Oncocyte secured reimbursement for VitaGraft™ Kidney, manufactured the initial lots of GraftAssure RUO, and entered a strategic partnership with Bio-Rad Laboratories to commercialize GraftAssure and develop VitaGraft Kidney IVD. This partnership, along with a successful $15.8 million private placement offering, positions Oncocyte well to meet its critical commercial and regulatory goals.
Oncocyte continues to be supported by strong core investors and aims to provide clarity and confidence to physicians and their patients through its groundbreaking diagnostic tests. For more information, visit www.oncocyte.com.
Oncocyte Corporation (OCX) announced the clinical launch of DetermaIO, the first immunotherapy response prediction test that assesses the tumor microenvironment, outperforming PD-L1 IHC. Recent data on Triple Negative Breast Cancer confirms its efficacy. The company reported a 65% year-over-year growth in test volume and raised its transplant monitoring capabilities with new IP. For Q3 2021, revenues reached approximately $1.0 million, a 77% increase from last year, though net losses grew to $13.8 million, or ($0.15) per share.
Oncocyte Corporation (Nasdaq: OCX) has launched the DetermaIO test, the first immunotherapy clinical test that evaluates the tumor microenvironment to predict patient responses to immunotherapy. Clinical studies have shown DetermaIO's accuracy in identifying potential responders, offering significant advantages over existing biomarkers like PD-L1.
The test aims to assist over one million patients annually in the U.S. in selecting effective immunotherapy treatments. Initial interest from physicians is high, and DetermaIO will be integrated with other tests for comprehensive patient management.
Oncocyte Corporation (Nasdaq: OCX) announced the issuance of U.S. Patent No. 11,155,872 for its Therasure Transplant Monitor, enhancing its intellectual property in the $2 billion U.S. transplant market. This blood-based test for organ rejection minimizes the need for invasive biopsies. The company plans to launch a lab-developed test (LDT) by Q1 2022 and aims for FDA submission of a kitted product by H1 2023. The patent fortifies Oncocyte's position in blood-based monitoring, and its technology offers cost-effective monitoring for transplant recipients.
Oncocyte Corporation (Nasdaq: OCX) will announce its third-quarter financial results for the period ended September 30, 2021, on November 9, 2021. A conference call is scheduled for the same day at 4:30 pm ET to discuss the results and corporate developments. Oncocyte focuses on precision diagnostics for cancer, with tests like DetermaRx™ and DetermaIO™ aimed at improving patient outcomes. The company emphasizes its commitment to advancing cancer care through proprietary tests and services, which assist in diagnosis, treatment planning, and monitoring.
Oncocyte Corporation (Nasdaq: OCX) has announced the appointment of Gisela A. Paulsen as the new Chief Operating Officer (COO). With over 20 years of experience in global change management and innovation in diagnostics and pharmaceuticals, Paulsen is expected to drive strategic growth and maximize opportunities within the company. Previously, she served as General Manager at Exact Science’s Precision Oncology and held significant roles at Roche/Genentech. Her appointment is anticipated to enhance Oncocyte's operational capabilities at a critical phase for growth in precision oncology diagnostics.
Oncocyte Corporation (Nasdaq: OCX) has announced peer-reviewed data supporting the effectiveness of its DetermaIO™ test in predicting responses to immunotherapy in high-risk early-stage triple-negative breast cancer (TNBC). Published in the journal Cancers, the study indicates that DetermaIO outperforms the standard PD-L1 IHC biomarker. The test's predictive ability was validated using biopsy samples from 55 patients involved in a neoadjuvant clinical trial. This research highlights DetermaIO's potential to guide treatment decisions early on, enhancing patient outcomes.
Oncocyte Corporation (OCX) announced positive results from the NeoTRIPaPDL1 clinical trial, showcasing DetermaIO as a predictive biomarker for immune therapy response in triple-negative breast cancer (TNBC). The trial enrolled 241 patients across multiple countries, demonstrating a 71% response rate for IO score positive patients receiving both immunotherapy and chemotherapy. This contrasts significantly with a 51% response rate in the chemotherapy-only group. DetermaIO's potential for pan-cancer application and its forthcoming clinical launch in Q4 2021 could tap into a $3 billion US market.
Oncocyte Corporation (Nasdaq: OCX) announced two key opinion leader (KOL) events focusing on advancements in cancer diagnostics. The first event, on September 22, will cover transplant rejection testing, featuring KOL Dr. Michael Oellerich, who will discuss unmet medical needs and Oncocyte's recent acquisition of capabilities for immunosuppressive therapy monitoring. The second event, on September 28, will focus on DetermaIO™, a gene expression test for triple-negative breast cancer. KOLs Dr. Priyanka Sharma and Dr. Giampaolo Bianchini will present data from a clinical trial evaluating DetermaIO as a biomarker for immunotherapy response.
Oncocyte Corporation (Nasdaq: OCX) has been recognized by Modern Healthcare as one of the 2021 Best Places to Work in Healthcare. The award highlights Oncocyte’s commitment to enhancing patient outcomes through its precision diagnostics and monitoring services. Ron Andrews, President and CEO, emphasized the company's dedication to its employees and mission during the challenges posed by the pandemic. The final ranking will be announced at the awards gala on September 16, 2021, in Chicago, showcasing the significant recognition of the company's workplace culture and its positive impact on healthcare.
Oncocyte Corporation (Nasdaq: OCX) announced the first evaluation of its DetermaIO™ assay in a randomized clinical trial for triple-negative breast cancer (TNBC). This groundbreaking study will be presented at the European Society for Medical Oncology (ESMO) Congress from September 16-21, 2021. The late-breaking oral presentation, titled Predictive value of gene-expression profiles in the Neo TRIPaPDL1 trial, will occur on September 20 at 1:30 PM EST. DetermaIO aims to predict patient responses to immuno-oncology therapies, enhancing treatment decision-making.
FAQ
What is the current stock price of Oncocyte Corporation (OCX)?
What is the market cap of Oncocyte Corporation (OCX)?
What does Oncocyte Corporation specialize in?
What types of cancer does Oncocyte's diagnostics target?
What are some of Oncocyte's key products?
How does Oncocyte's DetermaIO™ test work?
What recent achievements has Oncocyte made?
Who are some of Oncocyte's partners?
What is the purpose of Oncocyte's VitaGraft™ test?
What is GraftAssure™ used for?
How does Oncocyte support its operations financially?
Where can I find more information about Oncocyte Corporation?
